Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

11.94 -0.49 (-3.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc. - Common Stock

< Previous 1 2 Next >
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy
The research firm expects key clinical data in late 2025 and sees Ziihera royalties funding pipeline development. 
Via Stocktwits
Exposures Product Safety
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
From Zymeworks Inc.
Via GlobeNewswire
Earnings Scheduled For May 8, 2025
Via Benzinga
Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Deep Dive Into Zymeworks Stock: Analyst Perspectives (10 Ratings)
Via Benzinga
In-Depth Examination Of 9 Analyst Recommendations For Zymeworks
Via Benzinga
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves. 
Via Benzinga
Topics Earnings
Exposures Financial
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Earnings Scheduled For March 5, 2025
Via Benzinga
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Zymeworks in Focus for Insider Activity: Catalysts Ahead
Zymeworks' insider EcoR1 Capital is buying shares ahead of expected catalysts in 2025 that could drive the stock price to multiyear highs. 
Via MarketBeat
Exposures Product Safety
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
From Zymeworks Inc.
Via GlobeNewswire
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone. 
Via Benzinga
Exposures Product Safety
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
From Zymeworks Inc.
Via GlobeNewswire
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers 
From Zymeworks Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.